Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26851453)
Watch
English
Silymarin for HCV infection
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
title
Silymarin for HCV infection
(English)
1 reference
stated in
PubMed
author
Jean-Michel Pawlotsky
series ordinal
6
0 references
Harel Dahari
series ordinal
4
object named as
Harel Dahari
1 reference
stated in
Crossref
author name string
Stephen J Polyak
series ordinal
1
1 reference
stated in
Crossref
Nicholas H Oberlies
series ordinal
2
1 reference
stated in
Crossref
Eve-Isabelle Pécheur
series ordinal
3
1 reference
stated in
Crossref
Peter Ferenci
series ordinal
5
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
2013
1 reference
stated in
PubMed
published in
Antiviral Therapy
1 reference
stated in
PubMed
volume
18
1 reference
stated in
PubMed
issue
2
1 reference
stated in
PubMed
page(s)
141-7
1 reference
stated in
PubMed
cites work
Identification of hepatoprotective flavonolignans from silymarin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
7 April 2017
Multitargeted therapy of cancer by silymarin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
7 April 2017
Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
7 April 2017
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
7 April 2017
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Understanding silibinin's modes of action against HCV using viral kinetic modeling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Milk thistle in liver diseases: past, present, future
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Multiple effects of silymarin on the hepatitis C virus lifecycle
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Drug-drug interactions of silymarin on the perspective of pharmacokinetics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 September 2017
Pharmacokinetic studies with silymarin in human serum and bile.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
31 May 2018
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Gram-Scale Purification of Flavonolignan Diastereoisomers from Silybum marianum (Milk Thistle) Extract in Support of Preclinical in vivo Studies for Prostate Cancer Chemoprevention
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4076489
retrieved
28 November 2018
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Substituent effects in the free radical reactions of silybin: radiation-induced oxidation of the flavonoid at neutral pH
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Results of two double-blind studies on the effect of silymarine in chronic hepatitis (author's transl)
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23011959
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.3851/IMP2402
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5022366
Fatcat ID
release_dn6ihssdkjcqvewhp736m5smiu
0 references
OpenCitations bibliographic resource ID
5022366
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5022366
PMCID
4076489
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5022366
PubMed ID
23011959
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5022366
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
